The efficacy of sanjietongqiao prescription in the treatment of children with adenoid hypertrophy

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100052064

Enrollment

Unknown

Registered

2021-10-16

Start date

2021-11-14

Completion date

Unknown

Last updated

2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

adenoid hypertrophy

Interventions

Experimental group:Sanjietongqiao prescription

Control group:Montelukast Sodium (MS) combined with Mometasone Furoate Nasal Spray Nasal Spray (MFNSNS)

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Consistent with the diagnosis of adenoid hypertrophy: 1. Chief symptoms: snoring, mouth opening breathing, nasal obstruction, apnea during sleep; 2. Other symptoms: throat discomfort, inability to concentrate, emotional irritability, and unresponsiveness; 3. Adenoid face: depressed nasal root, elongated jaw, thick lip, external protrusion of upper incisors, dull face; 4. Complementary examinations: including lateral X-ray of nasopharynx and nasopharyngoscopy.

Exclusion criteria

Exclusion criteria: Incomplete information acquisition, affecting outcome statisticians.

Design outcomes

Primary

Measure	Time frame
Points scale for major signs and symptoms;	—

Countries

China

Contacts

Public ContactZhao Min

Shandong University of Traditional Chinese Medicine

1401338259@qq.com+86 18363080115

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026